Today, the President & Chief Executive Officer of ESSA Pharma (EPIX), David R Parkinson, bought shares of EPIX for $50K.
This recent transaction increases David R Parkinson’s holding in the company by 50% to a total of $169.2K. In addition to David R Parkinson, 5 other EPIX executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.31 and a one-year low of $1.46. Currently, ESSA Pharma has an average volume of 49.82K.
Starting in August 2019, EPIX received 14 Buy ratings in a row. Based on 3 analyst ratings, the analyst consensus is Strong Buy with an average price target of $8.67, reflecting a -21.6% downside. Three different firms, including Bloom Burton and Oppenheimer, currently also have a Buy rating on the stock.
The insider sentiment on ESSA Pharma has been positive according to 19 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.